Purpose: Changes in patient volume, due to tumor shrinkage, dehydration, dysphagia and atrophy, could present issues in the accuracy of dosimetry throughout the course of treatment.
: Integral Dose calculation for the asymmetric phantom scenario, displaying all of the organs and the difference in energy delivered to each when comparing five layers of bolus to zero. (Note: 1.02 g/cm 3 for soft tissue, 1.6 g/cm 3 for bone and 0.6 g/cm 3 for oral cavity due to combination of tissue and air.).. 
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• Assistance with the creation and planning of Asymmetric Phantom. Patients from 1985 to 1996 were evaluated in this research. The method of radiation delivery is not mentioned, but due to the timeframe in which patients were treated, we can assume that intensity modulated radiation therapy (IMRT) was not incorporated. This study did show, however, that 32.7% of head and neck cancer patients suffered severe weight loss. Severe weight loss is defined here as a loss of: > 10% of usual body weight (UBW) in 6 months, > 5% of UBW in 1 month, > 2% of UBW lost in 1 week, or > 7% of body mass index in 6 months. Although this study was evaluating the need for prophylactic gastrostomy tubes, it clearly shows that radiotherapy to the head and neck causes significant volume loss. The issue of volume loss in head and neck cancer treatment has been a long-standing clinical challenge and for this reason, a phantom study was conducted to investigate the dosimetric impacts of these volumetric changes in patients. In the method of intensity modulated radiation therapy (IMRT), the treatment is designed to deliver the prescribed dose of radiation to the tumor, while limiting the dose to organs at risk as much as clinically possible. The incidence of volume loss could be decreased by the implementation of IMRT, but head and neck cancer patients still experience significant volume loss due to tumor shrinkage and malnutrition. Radiation to the throat causes mucositis (inflammation of the mucosa), which leads to difficulty swallowing and pain. This can lead to malnutrition and dehydration, which then increases the likelihood of further volume loss. The precision and accuracy needed to achieve successful IMRT treatment can be compromised by the aforementioned volumetric changes.
INTRODUCTION

Motivation
The standard of care for evaluation of volumetric changes is to acquire a cone beam computed tomography (CBCT) scan at specific intervals during the patient's treatment. This scan will provide information about any change within the treatment volume. There are other techniques that can be utilized to monitor changes in patients. Examples of these techniques are taking weekly AP and Lateral source-to-skin measurements or acquiring on-board-imaging of the set up fields. The information from these techniques is analyzed and evaluated to monitor the patient's progress and possible changes.
The goal of this work is to evaluate the feasibility of the electronic portal-imaging device (EPID) to estimate these changes and possibly predict intervention of the patient's treatment plan.
In a study done by Dirkx et al., the portal imager was used to perform dosimetric measurements of each treatment field during IMRT, to ensure that the treatment that was planned and the radiation that was delivered both agree. By combining the dose fluence maps collected and knowledge of the patient set up the 3D dose distribution to both the tumor volume and organs at risk can be assessed. (Dirkx, et al., 2006, p.70-79) This study also agrees that a CBCT is still the best way to gain exact knowledge of the patient's internal geometry. The EPID was utilized in my study to acquire beam fluence exiting the phantom and was investigated for its ability to predict the dosimetric impacts of known volumetric changes applied to the phantom. This could lead to a more patient specific treatment strategy in which treatment can be adjusted and replanned before volumetric changes become significant enough to be detrimental to the patient.
Project Overview
Changes in patient volume could present issues in the accuracy of dosimetry throughout the course of treatment. The aim of this work is to investigate the dosimetric impacts of volumetric changes during IMRT in a phantom study using the EPID. This is a versatile imaging device mounted to most modern linear accelerators.
"The EPID was utilized with continuous frame-averaging during the beam delivery.
Properties studied included effect of buildup, dose linearity, field size response, sampling of rapid multileaf collimator (MLC) leaf speeds, response to dose-rate fluctuations, memory effect, and reproducibility. EPID measurements were also compared to ion chamber and film for open and wedged static fields and IMRT fields. The EPID was linear with dose and dose rate, and response to MLC leaf speeds up to 2.5 cm s -1 was found to be linear." (Greer, P. and Popescu, P., 2003) EPID has been demonstrated to be capable of evaluation of the phantom the study described herein where the EPID was utilized to investigate the feasibility of it predicting the dosimetric impacts caused by volumetric changes. By removing the bolus created in each scenario, I simulate changes that may possibly occur to patients throughout treatment. Images of the variations are captured by the imager and are compared to evaluate the variability in intensity of each image.
MATERIALS AND METHODS
Phantom Creation
Aquaplast TM Bolus (WFR Aquaplast TM Q-Fix TM Systems, PA) was applied to a Rando Figure 1 demonstrates the symmetric phantom, where five layers of bolus were formed around the phantom's surface. The Aquaplast TM Bolus is used to achieve very conformal, evenly distributed layers around the phantom. The bolus can be melted down in a warm water bath and formed around the phantom. Five layers of bolus were created so that each could be removed to resemble volumetric loss of the tissue around the head and neck.
The previously described technique was utilized in a second phantom scenario. Figure 2 demonstrates the bolus created on this phantom, unilaterally placed to simulate large tumor extension deforming the "normal" skin surface. On the asymmetric phantom we used rectangular sections of bolus that we molded from the left mandible to the left clavicle. Each of the five layers of bolus are equal thickness and equal dimensions. As in the symmetric phantom, I used five, 2.2 mm tissue equivalent, layers of bolus. These were held in place by several pieces of tape, and the surface of the phantom was marked for accurate placement of the bolus and reproducibility. The phantom was then set up on a head and neck immobilization device and fitted with an Aquaplast TM mask and simulated following protocols established for patients treated at Duke University Radiation Oncology. Figures 3 and 4 illustrate the mask position on the symmetric and the asymmetric phantom, respectively. This mask is used in the treatment of head and neck cancer to position the patient in a reproducible manner and to have a place to mark the patient 6 without having to place marks directly on their skin. This mask is securely placed on the bridge of the nose of each patient to ensure that they are in the exact position every day for treatment.
The mask is fastened to the AQ-fix head and neck board to further assure us of the phantom being in proper position. 
Planning
A computed tomography (CT) scan of the phantom was acquired for dosimetric planning of treatment to the head and neck. This was done for both the symmetric and asymmetric phantom scenarios. Using a GE CT Simulator, a scan was done with all five layers of bolus on the phantom, to start, and then one layer of bolus was removed and another scan was performed.
This step was repeated until there were zero remaining layers of bolus.
Figure 5: CT Set Up of Phantom Using GE CT Simulator
As each layer of bolus was removed, we carefully re-positioned the phantom to centering marks that were made on the mask and on the body of the phantom prior to the first scan using lasers in the room that converge at the center of the scanner. The CT data from each scenario were then exported to the Eclipse Planning System version 8.2. The phantom data was evaluated and each organ involved was contoured. were created so that none of the target volume extended outside the surface of the phantom when no bolus was applied. If the tumor was to extend into the bolus layers, it could introduce unpredictable variations in our set up as the layers were removed. In the symmetric set up, using the scan with five layers of bolus, we designed a nine-field IMRT plan based on a pre-existing clinical treatment of a patient that has superior and inferior borders that fit well within the size of our bolus. The prescribed dose was 2.0 Gray/fraction for 10 fractions, with limiting constraints to the organs at risk used in Duke radiation oncology for head and neck cancer treatment. Table 1 demonstrates the beam geometry for the symmetric set up, along with the monitor units needed to achieve the desired plan. This plan was applied to all layers of bolus material while holding all treatment geometry and parameters the same. The same number of monitor units was to be delivered to each phantom as the bolus was removed. This would introduce the fluctuation in dose delivered to each organ. The optimization used in head and neck treatment planning was not used in this case, or the asymmetric case, because the interest of this study was not to deliver a perfect treatment. I am investigating the EPID's ability to compare images of the integrated dose delivered, as the bolus material is removed, to see if it is a feasible technique to be further investigated. For the asymmetric set up we created a nine-field IMRT plan to encompass the bolus that extended and deformed the "normal" surface of the phantom. The planned target volume was designed to be 3.0mm below the surface of the bolus to simulate skin over the surface of the phantom. Table 2 shows the beam geometry, beam orientation and total monitor units to deliver at each beam. Field 1 was split into two carriages in order to deliver the entire field. They are the same orientation but split in order to extend beyond the limit of the multi-leaf collimator. The combined total of monitor units for field 1a and 1b is 149. The prescribed dose was 2.0 Gray/fraction for 25 fractions, to be delivered on a Varian Novalis Tx System (Varian, CA), with the same constraints used in the symmetric phantom plan. The dose-volume histogram (DVH) was generated with the Eclipse planning system prior to treatment of the phantom. This DVH was used to evaluate the predicted variability (from Eclipse) in dose to all of the contoured organs within the phantom. 
Treatment Delivery
The phantom was set up in the treatment room, orthogonal images were acquired for initial set up and a cone beam CT (CBCT) was performed to verify further positioning accuracy.
The OBI/CBCT device is a diagnostic quality x-ray device that provides us with positioning information of the bony anatomy of a patient in planar imaging, and soft tissue positioning information in CBCT mode. Orthogonal planar images acquired fro the anterior/posterior position and the left lateral position. The EPID was then set to the integrated dosimetry mode, and the treatments were delivered. The EPID used on the Varian Novalis TX consists of an amorphous silicon layer that is a photodiode array of 1024 x 1024 pixels, with a pixel size of 400 µm x 400µm. Thereby resulting in a 41cm x 41 cm imaging surface and a 27cm x 27 cm effective field size at isocenter, with a source to detector distance of 160cm. The electronics for digital readout of the detected image are protected by shielding and internal design of the portal imager (McDonough, et al, 2002) . The treatment plan of the phantom set up with five layers of bolus was utilized for all treatments of the phantom in both cases. Three treatments were delivered for each number of bolus layers to verify precision and accuracy, and all images were collected to be analyzed post treatment. After each layer of bolus was removed, another CBCT was performed to maintain set up accuracy. All images were imported to Matlab and a gamma analysis was performed to evaluate intensity changes in images of different total volumes of bolus with criteria of 3%/3mm dose difference and distance-to-agreement, respectively.
Image Acquisition
The Gamma Distribution
The Gamma distribution is a means to quantify and compare dose distributions captured by the EPID. This quantity is calculated independently for each point, from one image to the next, to measure the dose agreement and distance to agreement. Dose agreement is defined as the planned dose measured against the dose delivered to a specific point. The distance to agreement means that if dose difference is not satisfied then planned points are searched within a user defined radius (3mm in our case) for a value that corresponds to the measured point at the center radius. The criteria used are 3% dose and 3mm distance to agreement. (Low, D., 1998) Figure 9 visually demonstrates the dose and distance to agreement when the calculated dose is measured against the measured dose. This evaluation is performed using the formula below to calculate the gamma value for every pixel.
Equation 1: Gamma index where ΔD t is tolerance dose (3%), ΔD is the measured dose, Δd t is the tolerance distance to agreement (3 mm) and Δd is the measured distance to agreement.
For each pixel in the calculated dose map the γ index is evaluated. The calculation for each pixel uses Equation 1 to find the min(Γ). The γ index over all pixels provides us with a γ map and failed pixels have a value γ > 1.0 (Das, S., Lecture 21, 2009 ). This gamma analysis was then correlated and compared to the predicted variations from the planning software. The gamma function is utilized in the Matlab code, and was used to evaluate the images of varying layers of bolus in a specific phantom situation and for each beam angle. The gamma was used to evaluate images of exactly the same number of bolus with no variables changed to establish a consistency evaluation of the EPID. In this study, the images of each layer of bolus material were compared to each subsequent layer, along with comparing all five layers to each other amount. This was used to establish what would be a baseline from the first day of treatment. This baseline is then compared to changes in the phantom that simulate tissue loss throughout treatment.
RESULTS
Eclipse Planning Predictions
In the symmetric scenario, plans were generated using an existing critical organ set of contours and a planned target volume (PTV) that fit within the upper and lower boundaries of our bolus placement. The PTV is defined in the treatment uncertainties, such as organ motion and set up positioning error and incorporates the concepts of internal margin and setup margin to account for these uncertainties. To gain a better understanding of the dose change within the tissue, the clinical target volume was used for our investigation of dose fluctuation. The clinical target volume (CTV) is the volume of interest in this study because it is this volume that is to be sterilized and eradicated in clinical radiation oncology. The CTV includes the gross tumor volume (GTV) and subclinical microscopic malignant disease. GTV is defined as gross palpable or visible extent of malignant growth (Kahn, F., pp. 45, 1998) . For the asymmetric set up the plan was created using the bolus as a significant amount of the tumor volume. The doses were calculated by using the plan with maximum bolus in both situations. This was done to simulate a patient beginning treatment and would allow for changes to occur in the treatment volume during treatment. The PTV in this case is designed to be 3 mm below the bolus surface to account for skin, and extended into the phantom below the surface. The CTV in this scenario decreased in volume with the removal of bolus material to resemble tumor CTV shrinking as a result of the treatment. The dose volume histograms were plotted for the most extreme cases of comparison.
14 Using the DVH generated in Eclipse planning system, the integral dose delivered to each organ was evaluated for each of the phantom scenarios, and for all layers of varying bolus.
Using the integral dose, which is defined as the amount of energy deposited in the entire organ, we can evaluate how the dose varies when bolus material is removed. Eclipse generates the estimated information needed to calculate the integrated dose. Being that we are working with a finite number of samples of tissue, the integral can be approximated as a summation as in equation (4).
17
The mean dose value is given to us in Eclipse as cGy, which is easily converted to mGy.
The Gray is a unit of dose defined as: 1 GY = 1 Joule/kilogram and the mGy is milliJoule/kilogram, which converts to microJoule/gram. The equations above result in the S.I. unit of microJoules delivered to the entire organ. Then the calculation of integral dose difference between the five-layer bolus phantom and the zero-layer bolus phantom for each of our set up designs was calculated. As stated in section 2.2, the prescribed dose for this phantom scenario is 2.0 Gy/fraction, for 10 fraction. The total dose calculated is 2,000 cGy to the PTV. The prescribed dose for the asymmetric phantom scenario is 2.0 Gy/fraction for 25 fractions, resulting in 5,000 cGy to the PTV. Using the information provided in eclipse, the integral dose calculations were performed and the results of these calculations are displayed on Tables 3 and 4 below. Tables 3 and 4 tell us about what happens to the entire organ, which can be useful information when considering parallel organs like the parotid gland. Parallel organs are organs that can tolerate larger treatments to a portion of the organ and still maintain function of the rest of the non-irradiated part of the organ. The evaluation of serial organs, like the spinal cord, leads to more challenging problems. A serial organ is an organ that if even a small portion is treated beyond its tolerance dose will lose all function. In this table, we are spreading the dose out to the entire organ and not getting an accurate account of the highest doses and where they are being delivered. Evaluation of Table 4 tells us that, as in the symmetric phantom, the greatest percent differences occur in the organs receiving far less than the clinical target volume. In this case the CTV's integral dose increases by approximately 4.5 %. The rest of the organs at risk receiving more than half of the prescribed dose (2500 cGy), have very low percent changes in integral dose. Table 3 , we do need to be concerned about the serial organs and how to determine their maximum dose and volume being treated at that maximum value. Table 5 shows the gamma analyses of images taken of exactly the same amount of bolus.
As in
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EPID Consistency Evaluation
The treatment was delivered three consecutive times with no variables changed, and the integrated dose image was saved for each beam of each treatment. This image comparison demonstrates the accuracy of the portal imager to collect the integrated dose and the ability of our gamma analysis to detect differences in these images. The data verifies that the imager can consistently collect integrated dose and that our comparison analyses are valid. A perfect pass rate would be 1.00 (100% pass) and this data shows that all image sets have passing rates higher than 0.996 (99.6% pass). Therefore, we can assume that the EPID has a linear response to changes in bolus thicknesses in this experiment. Table 6 : Gamma Analysis of symmetric phantom comparing 5 layers of tissue equivalent to each subsequent layer, simulating tissue loss throughout treatment. Perfect pass = 1.00
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Evaluation of Integrated Dose Imaging of Symmetric Phantom
As illustrated in Table 6 , the gamma index evaluation of images shows the highest variability in the images with five layers of bolus when compared to images with no bolus, the most significant being the posterioanterior (PA) field showing a gamma pass rate of 54.62%. The highest pass rate is shown in this situation is in the second right posterioanterior (RPO2) field. shrinkage. This leads us to the next phantom evaluation, asymmetric bolus removal. Table 7 shows the collected data for the asymmetric phantom gamma analysis. Overall, the percent pass rates are much higher than the values from the symmetric set up. The least percentage of agreement, in this data set, is the right anterior oblique field. This makes sense due to the tangential nature of this beam. The bolus removal in this orientation comprises the majority of the image and therefore presents itself as a variation in the gamma index. 
Evaluation of Integrated Dose Imaging of Asymmetric Phantom
DISCUSSION
Advantages of Using EPID for Integrated Dose Image Analysis
This project demonstrates that images captured by the EPID can be used for patient volume analysis. When the image varies over time a large percentage of the integrated dose image will fail the gamma index when compared to the baseline image. Upon the initiation of treatment, capturing the integrated dose image is a simple addition to the delivery of treatment to the patient. Utilizing exit dose radiation to acquire useful information about the patient treatment volume is a very efficient means of investigation. There is no additional ionizing radiation administered to the patient and no additional imaging time added to the daily treatment. The images collected can be added to the patient's electronic chart and stored to use as a baseline of patient volume. This procedure also provides the ability to visualize the initial beam geometry for quality assurance of the IMRT treatment.
The symmetric phantom in this study was designed to lose five layers of 2.2mm bolus material. This is a moderate amount of tissue loss for a patient receiving external beam radiation therapy to the head and neck. Patients on treatment could possibly lose significantly more volume than our phantom design or could potentially not lose much volume at all. This procedure could monitor the loss of tissue in patients by analyzing the integrated dose images at a frequency determined by the attending physician or a department protocol. This process could be automated to evaluate the gamma analysis of the integrated dose images at a rate, specified by the designer of the protocol that would place an alert on the patient's chart that suggests when reevaluation is recommended. This process could be designed to be automatically implemented within the patient's chart. Currently, when patients begin treatment the physician determines whether he/she is in a higher risk category for potential re-planning due to volume change. The patients in this category tend to have larger tumor volumes or have a higher amount of body fat to lose. Also, patients who are not compliant with their nutritional plan would be placed in this higher risk group. At this time the physician must make a decision about when each patient should have volumetric imaging done to evaluate if there are changes in the planned treatment target. With this imaging it can be seen if the volume surrounding the tumor has shrunk, if the tumor has changed in mass or a combination of the two. The procedure investigated in this study would eliminate the guesswork by collecting images at regular intervals and analyzing them for the physicians. This procedure would then eliminate the need to scan patients on a CT scanner or with CBCT who we are unsure if they have changes. If the integrated dose images begin to drift out of agreement there will be a need to evaluate the patient with the "gold standard" of volume investigation, which is a CBCT or a diagnostic CT scan.
Limitations of EPID Integrated Dose Analysis
This study suggests that images can be evaluated for lack of agreement with the gamma index. This analysis method has some limitations that need to be taken into consideration. The gamma index pass rate will tell us how well the images match up to each other, but it does not have the ability to tell us whether the patient has decreased or increased volume. Patients being treated for head and neck cancer have tumors that tend to be very radiosensitive. This means that the tumors react very well to the treatment and will shrink. Some tumors can be very aggressive and radio-resistant. If the tumor gets larger the images we collect will still fail the gamma analysis, but not for the same reason suggested in this study. This will still suggest that the volume should be evaluated by a physician to potentially be re-planned. Also, the gamma index tends to have problems where there are large gradients of dose within the tissue. With IMRT treatment we design treatments with very small margins and therefore very steep gradients. This issue could present problems with the failure rates at the edges of the field and surrounding the tumor. Another source of failure might be set up error. If a patient is not set up correctly there can be deviations from the baseline image to the current image of interest. This would present itself as a reason for investigation and is potentially another benefit of this procedure.
Another limitation of this procedure is the size of the portal imager. The imager has an effective field size of 27 cm 2 . This limits the ability to evaluate large tumor volumes with the EPID. Most head and neck volumes are smaller than this, but it does present an issue for large tumors on large patients. Patients who could potentially benefit the most by a procedure like this one would tend to be larger patients who have later stage disease. When a patient is diagnosed with a later stage disease or with further extension into the tissue, the treatment will tend to be more damaging to the surrounding, normal structures and could cause more severe side effects of treatment. More severe side effects could lead to greater volume change during the course of treatment. Another possible issue is that the EPID has a source to imager distance of 160 cm. There could be potential collision issues with the table or patient, depending on the treatment design and beam geometry. Most centrally located tumors will not result in collision, but if there are lateral tumors, as in my asymmetric phantom scenario, this could be an issue.
CONCLUSION
This study demonstrates that volume loss contributes to changes in the dose delivered to the target volume and organs at risk. Our experimental data shows that changes that happen clinically could potentially be evaluated with the EPID and an alert could be integrated to make the physician aware of the potential for dosimetric fluctuations. These variations could possibly be detrimental to the patient's treatment by increasing dose to organs at risk and creating inaccuracies in the dose to the planned target volume. Investigation of the gamma analysis data collected suggests that symmetric volume loss has a much greater impact on the integrated image fluctuation than does the results of the asymmetric scenario. This is related to the beam positioning in relationship to the tumor volume.
Symmetric volume changes have a greater impact on dose delivered to the CTV and the organs at risk than do volume changes that are strictly superficial in nature. The data collected by the EPID agrees with the predictions of Eclipse about dose changes due to bolus removal on the phantom. Therefore, there could be a method integrated to automate this evaluation and make clinical suggestions about the need for dosimetric re-planning. As demonstrated in the phantom study, the proposed technique could provide valuable information about the variation of dose due to volumetric changes in the patient throughout treatment and could potentially be useful in the clinic.
Future investigation of the EPID needs to be done to evaluate greater volume loss of patients receiving IMRT to the head and neck. Evaluating 1.1 cm tissue loss is the first step.
Patients could lose far more than this while on treatment. The same set up could be used with larger amounts of bolus material and the same evaluation would be used. There also needs to be a phantom design that would simulate both a large patient and a large superficial tumor at the same time. This evaluation could provide information about the worst-case scenario.
Development of the software needed to implement this procedure would be the next step. We need an automated process of image evaluation and alert that could be easily implemented into the existing treatment software and hardware at the treatment console and off-line review.
After these steps are taken, the next phase is to evaluate patients on treatment. The "gold standard" of volume monitoring would be maintained by administering a CBCT or a diagnostic CT scan at the usual intervals established by the clinic or the attending physician while gathering integrated dose images and correlating these images to patient progress and advancement through treatment. This is an easily implemented procedure that could increase the efficiency of the clinic by addressing the issues of volume loss, tissue changes and real-time patient quality assurance all in one step. Understanding that it does have limitations, this process could assist the physician in his/her decision making about how and when to re-plan a patient who may be experiencing dramatic changes due to the radiation treatment. It is feasible that the EPID could be used to evaluate volumetric changes in head and neck cancer patients receiving IMRT.
